Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gevokizumab - Novartis

Next Previous
Drug Profile

Gevokizumab - Novartis

Alternative Names: S-78989; VPM 087; XMA-005.2; XMA-0052; XOMA-052

Latest Information Update: 17 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XOMA
  • Developer IRIS; National Eye Institute; North Shore-Long Island Jewish Health System; Novartis; Servier; University of Zurich; XOMA
  • Class Anti-inflammatories; Antiacnes; Antigouts; Antihyperglycaemics; Antineoplastics; Antirheumatics; Cardiovascular therapies; Ear disorder therapies; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Interleukin 1beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pyoderma; Uveitis; Behcet's syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Colorectal cancer; Gastric cancer; Oesophageal cancer; Renal cell carcinoma
  • Discontinued Acne vulgaris; Acute coronary syndromes; Diabetic nephropathies; Giant cell arteritis; Gout; Juvenile rheumatoid arthritis; Labyrinthitis; Myositis; Osteoarthritis; Pyoderma; Rheumatoid arthritis; Schnitzler syndrome; Scleritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus; Uveitis

Most Recent Events

  • 14 Jul 2026 XOMA has been acquired by Ligand Pharmaceuticals
  • 28 Feb 2026 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, First-line therapy, Metastatic disease) in Australia (IV)
  • 28 Feb 2026 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, First-line therapy, Metastatic disease) in Belgium (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top